IgE antagonists
AssigneesThomas Jefferson University, King's College
InventorsBradford A. Jameson, Brian J. Sutton, James M. McDonnell, Hannah J. Gould, Robert Korngold, Andrew J. Beavil
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for modulating interaction between IgE and Fc.epsilon.R1. The present invention also relates to compounds that modulate IgE binding to Fc.epsilon.R1.
Claims29
A peptide consisting of up to 25 amino acids, wherein said peptide
- a) comprises at least a fragment of SEQ ID NO:3 of at least 6 amino acids and
- b) is capable of modulating IgE binding to Fc.epsilon.R1.
A peptide consisting of up to 25 amino acids, wherein said peptide
- a) comprises SEQ ID NO:3 and
- b) is capable of modulating IgE binding to Fc.epsilon.R1.
A peptide consisting of up to 25 amino acids, wherein said peptide
- a) comprises at least a fragment of SEQ ID NO:3 of at least 6 amino acids
- b) has an amino terminal cysteine and a carboxy terminal cysteine which are linked by a disulfide bond and
- c) is capable of modulating IgE binding to Fc.epsilon.R1.
A pharmaceutical composition comprising:
- a) a peptide consisting of up to 25 amino acids, wherein said peptide
- i) comprises at least a fragment of SEQ ID NO:3 of at least 6 amino acids and
- ii) is capable of modulating IgE binding to Fc.epsilon.R1;
- and
- b) a pharmaceutically acceptable carrier or diluent.
A peptide consisting of 6-50 amino acids, wherein said peptide
- a) comprises SEQ ID NO:5 and
- b) is capable of modulating IgE binding to Fc.epsilon.R1.
A pharmaceutical composition comprising:
- a) a peptide consisting of 6-50 amino acids, wherein said peptide
- i) comprises SEQ ID NO:5 and
- ii) is capable of modulating IgE binding to Fc.epsilon.R1;
- and
- b) a pharmaceutically acceptable carrier or diluent.
A method of inhibiting IgE binding to Fc.epsilon.R1 on cells comprising the steps of:
- contacting cells that contain the Fc.epsilon.R1 with an amount of a peptide sufficient to inhibiting IgE binding to Fc.epsilon.R1, wherein said peptide
- a) consists of 4-50 amino acids,
- b) comprises at least a fragment of SEQ ID NO:3 of at least 4 amino acids.
A method of inhibiting IgE binding to Fc.epsilon.R1 on cells comprising the steps of:
- contacting cells that contain the Fc.epsilon.R1 with an amount of a peptide sufficient to inhibit IgE binding to Fc.epsilon.R1, wherein said peptide
- a) consists of 6-50 amino acids,
- b) comprises SEQ ID NO:5.
A method of therapeutically or prophylactically treating an individual suspected of suffering from or being susceptible to an immediate allergic response comprising the steps of:
- administering to said individual an effective amount of a peptide which:
- a) consists of 4-50 amino acids,
- b) comprises at least a fragment of SEQ ID NO:3 of at least 4 amino acids, and
- c) inhibits IgE binding to Fc.epsilon.R1.
A method of therapeutically or prophylactically treating an individual suspected of suffering from or being susceptible to an immediate allergic response comprising the steps of:
- administering to said individual an effective amount of a peptide which:
- a) consists of between 6 and 50 amino acids,
- b) comprises SEQ ID NO:5, and
- c) inhibits IgE binding to Fc.epsilon.R1.
A peptide dimer comprising a first monomer and a second monomer wherein
- a) said first monomer
- i) consists of 4-50 amino acids,
- ii) comprises at least a fragment of SEQ ID NO:3 of at least 4 amino acids and
- b) said second monomer
- i) consists of 6-50 amino acids,
- ii) comprises SEQ ID NO:5;
- wherein said dimer is capable of inhibiting IgE binding to Fc.epsilon.R1.
A peptide consisting of amino and carboxy terminal cysteines flanking SEQ ID NO:3 or a fragment thereof selected from the group consisting of amino acids 1-4, 2-5, 3-6, 4-7, 5-8, 6-9, 7-10, 8-11, 1-5, 2-6, 3-7, 4-8, 5-9, 6-10, 7-11, 1-6, 2-7, 3-8, 4-9, 5-10, 6-11, 1-7, 2-8, 3-9, 4-10, 5-11, 1-8, 2-9, 3-10, 4-11, 1-9, 2-10, 3-11, 1-10, and 2-11 of SEQ ID NO:3.
Dependencies are inferred from the claim text.